Domvanalimab + Zimberelimab for Liver Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to learn about advanced liver and bile duct cancers. The main question it aims to answer is:If the combination of Domvanalimab and Zimberelimab are effective in treating advanced hepatobiliary cancers that have failed prior treatment.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on antiviral therapy for hepatitis B, you should continue it throughout the study. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drug Domvanalimab + Zimberelimab for liver cancer?
Who Is on the Research Team?
David Hsieh, MD
Principal Investigator
Assistant Professor
Are You a Good Fit for This Trial?
This trial is for adults with advanced liver or bile duct cancer that's not suitable for surgery or has come back after treatment. They must have tried anti-PD-1/L1 therapy before, be in fairly good health (ECOG score 0-1), and have a certain level of liver function (Child-Pugh Score A/B7-B8). Pregnant women, HIV-positive individuals, those with recent major surgeries or trauma, autoimmune diseases requiring treatment within the past two years, severe allergies to monoclonal antibodies, active infections like tuberculosis, and anyone on high-dose steroids can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Zimberelimab (AB122) 360 mg IV and Domvanalimab (AB154) 1200 mg IV every three weeks until disease progression, unacceptable toxicity, or other discontinuation criteria
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Domvanalimab
- Zimberelimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor
Cancer Prevention Research Institute of Texas
Collaborator
Arcus Biosciences, Inc.
Industry Sponsor